TC
TVTX icon

Tavio Capital’s Travere Therapeutics TVTX Stock Holding History

Tavio Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-100,985
Closed -$2.29M – 14
2019
Q1 		$2.29M Hold
100,985
– – 0.84% 13
2018
Q4 		$2.29M Sell
100,985
-192,938
-66% -$4.8M 0.95% 15
2018
Q3 		$8.44M Hold
293,923
– – 3.29% 11
2018
Q2 		$8.01M Hold
293,923
– – 2.71% 15
2018
Q1 		$6.57M Hold
293,923
– – 3.1% 12
2017
Q4 		$6.19M Hold
293,923
– – 3.38% 8
2017
Q3 		$7.32M Hold
293,923
– – 2.98% 9
2017
Q2 		$5.7M Hold
293,923
– – 2.84% 10
2017
Q1 		$5.43M Buy
+293,923
New +$5.75M 2.78% 7

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tavio Capital's TVTX Position: Q2 2019 in Review

Tavio Capital sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 100,985 shares — an estimated $2.29M sold.

Tavio Capital first reported a position in TVTX in Q1 2017 and held it in 9 quarters. The position peaked at $8.44M in Q3 2018. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

  • Tavio Capital reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Tavio Capital sold 100,985 Travere Therapeutics shares in Q2 2019, an estimated $2.29M.
  • Tavio Capital first reported a position in Travere Therapeutics in Q1 2017 and held it in 9 quarters.
  • Tavio Capital's Travere Therapeutics position peaked at $8.44M in Q3 2018.
  • 122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Tavio Capital's 13F filing for Q2 2019, filed 13 Aug 2019.